A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Advanced or Recurrent Squamous Cell Cancer of the Cervix
- Determine the antitumor activity of DX-8951f in women with advanced or recurrent
squamous cell carcinoma of the cervix.
- Evaluate the quantitative and qualitative toxic effects of this regimen in these
- Evaluate the pharmacokinetics of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive DX-8951f IV over 30 minutes daily for 5 days. Courses repeat every 21 days
in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months until death.
PROJECTED ACCRUAL: Approximately 37 patients will be accrued for this study.
Primary Purpose: Treatment
Robert L. DeJager, MD, FACP
Daiichi Sankyo Inc.
United States: Federal Government
|University of Texas - MD Anderson Cancer Center||Houston, Texas 77030-4009|
|Brookview Research, Inc.||Nashville, Tennessee 37203|
|Albert Einstein Clinical Cancer Center||Bronx, New York 10461|
|Texas Oncology PA (TOPA) at Baylor-Sammons||Dallas, Texas 75246|
|St. Luke's-Roosevelt Hospital||New York, New York 10019|
|Ruppert Health Center||Toledo, Ohio 43614|